• Company
• Janssen makes first bid into lung cancer mkt with Rybrevant
• by May 24, 2022 05:55am

• Company
• Alvogen, 1 in 3 failed patent attempts for Avastin
• by Kim, Jin-Gu May 24, 2022 05:55am

• Policy
• Atopic Dupixent Pen will be available in Korea
• by Lee, Hye-Kyung May 24, 2022 05:54am

• Company
• Ilaris reattempts reimb for its 13 patients in Korea
• by Eo, Yun-Ho May 23, 2022 06:06am

• Company
• Keytruda became a new breakthrough in the tx
• by May 23, 2022 06:06am

• Company
• Keytruda leads sales for the 9th consecutive quarter
• by Chon, Seung-Hyun May 23, 2022 06:06am

• Company
• The global competitiveness of new drugs depends on
• by Nho, Byung Chul May 23, 2022 06:06am

• Company
• COVID-19 exports to Australia↑123 times in a year
• by Kim, Jin-Gu May 23, 2022 06:06am

• Policy
• Fexclu priced at 90% of the weighted average of K-CAB+PPIs
• by Lee, Tak-Sun May 20, 2022 06:12am

• Policy
• The MFDS will gradually disclose the results of GMP survey
• by Lee, Hye-Kyung May 20, 2022 06:11am